Level A· Stronger Clinical EvidenceSystematic ReviewEurope PMCOpen access

Worldwide hotspots and trends in stem cell therapy for kidney disease in the last decade: a bibliometric and visualization analysis from 2015 to 2024

Liao S., Zhang X., Zhou Y., Wang L., Chen C., Ye C.

Systematic Review on Chronic Kidney Disease, Acute Kidney Injury, published in Front Immunol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Front Immunol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40761782
PMCID
PMC12318756
DOI
10.3389/fimmu.2025.1619291
Citations
2

Abstract (original English)

Background Kidney disease represents a significant global health concern. Stem cell therapy has gained attention as a potential solution for chronic kidney disease, acute kidney injury, and end-stage renal disease. This study aims to provide a comprehensive overview of the status of stem cell therapy for kidney disease through a systematic review of the literature. Methods The literature included in this study was exclusively sourced from the Web of Science Core Collection. CiteSpace, VOSviewer, R-Bibliometrix, and the Literature Data Governance and Analysis System to evaluate factors such as publication quantity, author contributions, institutional involvement, geographic distribution, and keyword usage. Results This study on stem cell therapy for kidney disease included 1,874 articles. A significant number of publications came from China and the United States. The Mayo Clinic had the highest publication output, while Stem Cell Research & Therapy was the leading journal in terms of publication volume. Additionally, Lerman LO was the most prolific author in this field. Currently, there is a growing focus on mesenchymal stem cells and acute kidney injury models in this field. Future research is likely to explore topics such as extracellular vesicle-based therapies, various stem cell types, diabetic nephropathy, and membranous nephropathy. Conclusion This study applied bibliometr

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
AnimalsHumansKidney DiseasesStem Cell TransplantationBibliometrics

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research